Radium-223 in mCRPC

Radium-223 Chloride (Alpharadin) in Patients with Bone Metastases and Castration-resistant Prostate Cancer (CRPC): A New Treatment Paradigm

Professor Sartor discusses a study of CRPC patients with bone metastases which showed that radium-223 significantly prolonged overall survival and time to first skeletal-related event, and was well tolerated.

A. Oliver Sartor, MD
Laborde Professor of Cancer Research
Departments of Medicine and Urology
Medical Director of Tulane Cancer Center
Tulane School of Medicine
New Orleans, Louisiana